Company description

Regeneron Pharmaceuticals, Inc. (ticker: REGN) is an American biotechnology company that specializes in developing innovative medicines for serious medical conditions. Founded in 1988, Regeneron has become a leading biotech company in the industry, with a strong track record of successfully bringing innovative drugs to the market. Their focus on science and research has led them to develop groundbreaking treatment options for various diseases, such as cancer, eye diseases, and rare genetic disorders. The company's flagship product, EYLEA, has become one of the leading treatments for age-related macular degeneration and other eye-related diseases. Regeneron has collaborations with major pharmaceutical companies like Sanofi, to bring new drugs to the market. They also have a strong pipeline of new drugs in various stages of development, which shows promising potential for future growth. Regeneron is committed to improving patient outcomes, and their dedication to innovation and scientific excellence has established them as a global leader in biotechnology. With a strong financial performance and a passionate team of employees, Regeneron continues to make a significant impact in the healthcare industry.